Modified RNA Vaccine Against Influenza
Vaccineexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Sep 13, 2021 (NCT05052697)
Timeline
Indications
Mechanism of action
- Influenza A virusImmunity, active
Influenza A virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07213804 | Phase 3 | Oct 22, 2025 | Eli Lilly, European Network for Gynaecological Oncological Trial, GOG Foundation, Inc. |
| NCT05445778 | Phase 3 | Dec 31, 2022 | GOG Foundation, Inc., Immunogen |
| NCT05052697 | Phase 1 | Sep 13, 2021 | Pfizer |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GOG Foundation, Inc. | Academic/Hospital | 2 | 0 | 1 | 2022 |
| Eli Lilly | For profit | 1 | 1 | 1 | 2025 |
| European Network for Gynaecological Oncological Trial | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Immunogen | For profit | 1 | 1 | 1 | 2022 |
| Pfizer | For profit | 1 | 1 | 1 | 2021 |
5 organizations
Page 1 / 1